Adaptive, Dose-finding Phase 2 Trial Evaluating the Safety and Efficacy of ABT-089 in Mild to Moderate Alzheimer DiseaseRobert Lenz, Mario Saltarelli, Yili Pritchett et al.|Alzheimer Disease & Associated Disorders|2015Cited by 28